BioSpace News Archive

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform announces that it will be holding a shareholder update call on Thursday, Jan

CVS Health Corporation announced that its board of directors has approved a quarterly dividend of $0.50 per share on the corporation’s common stock.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew.

Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective January 1, 2021.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Dr. Robert Stein, Executive Vice President, Research & Development, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference held January 11-14, 2021. The pre-recorded fireside chat will be avail

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021. Arbutus Fireside Chat Pr

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the completion of its end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) on AL102, a potent, selective, oral gamma secretase inhibitor (GSI), for the treatment of desmoid tumors.

Forge Biologics Inc., a gene therapy manufacturing and development company, today announced that the company has received FDA clearance of the Investigational New Drug (IND) to initiate a Phase 1/2 clinical trial evaluating its novel, first-in-human AAV gene therapy, FBX-101, for patients with Krabbe disease

- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Week.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that the Company will participate in the H.C. Wainwright BioConnect 2021 Conference, being held virtually on January 11-14, 2021 .